CEO Steven Kelly described the scientific basis of pipeline changes they have made this week and when we can expect to see data.

Bill Newell describes this week’s deal with Ipsen, the folate receptor alpha space, and more.

Co-Founder and CEO Eric Murphy describes what it was like raising the money in this environment.

Dr. Bertozzi and Dr. Hsiao describe how Acepodia is leveraging biorthogonal chemistry to conjugate antibodies to allogeneic γδ2 T cells.

CEO Lawrence Klein describes advances in antibody engineering Oruka is leveraing to make improved IL-23 and IL-17 inhibitors.

Sek Kathiresan describes what Verve believes caused elevated liver enzymes and thrombocytopenia in a PCSK9 gene editing trial.

Thomas Shrader shares his thoughts on biotech and comments on companies he covers.

Peter Maag describes how Kyverna has been focused on this area for five years.

Paul Hastings describes why Nkarta believes NK based therapies are uniquely fit for this area.

John Scarlett shares his take on imetelstat's clinical utility, potential commercial dynamics, the IP situation, and more.

BiotechTV visited the Freemont, CA headquarters of Ultima Genomics and spoke with CEO Gilad Almogy about their approach.

Andy Hsieh gives his take on the radiopharmaceutical space, Viking’s obesity data, Pyxis Oncology, Cardiff Oncology, Fibrogen.

Founder Mark McKenna describes the unmet need that exists in the I&I space.

Alexandria Forbes describes the investments MeiraGTx has made in manufacturing and how it is helped progress various programs.

Evan Seigerman breaks down which companies and technologies are at the forefront of the the GLP space.

Ali Gorman will be covering biotech news and cool research in the greater Philadelphia area for BiotechTV.

Matt Phipps covers Janux, NewAmsterdam, Jasper, Autolus, Incyte, Merus, and Amgen.

Laura Chico gives her take on the state of biotech and discusses Denali, Praxis, Viridian, Apellis, PepGen, and Edgewise.